Hays Documentation Specialists, LLC, 225 Virginia Avenue, 2B, San Mateo, CA, 94402, USA.
Eur J Med Res. 2024 Nov 19;29(1):553. doi: 10.1186/s40001-024-02138-2.
Cytopathological examination serves as a tool for diagnosing solid tumors and hematologic malignancies. Artificial intelligence (AI)-assisted methods have been widely discussed in the literature for increasing sensitivity, specificity and accuracy in the diagnosis of cytopathological clinical samples. Many of these tools are also used in clinical practice. There is a growing body of literature describing the role of AI in clinical settings, particularly in improving diagnostic accuracy and providing predictive and prognostic insights.
A comprehensive search for this systematic review was conducted using databases Google, PUBMED (n = 450) and Google Scholar (n = 1067) with the keywords "Artificial Intelligence" AND "cytopathological" and "fine needle aspiration" AND "Deep Learning" AND "Machine Learning" AND "Hematologic Disorders" AND "Lung Cancer" AND "Pap Smear" and "cervical cancer screening" AND "Thyroid Cancer" AND "Breast Cancer" and "Sensitivity" and "Specificity". The search focused on literature reviews and systematic reviews published in English language between 2020 and 2024. PRISMA guidelines were adhered to with studies included and excluded as depicted in a flowchart. 417 results were screened with 34 studies were chosen for this review.
In the screening of patients with cervical cancer, bone marrow and peripheral blood smears and benign and malignant lesions in the lung, AI-assisted methods, particularly machine learning and deep learning (a subset of machine learning) methods, were applied to cytopathological data. These methods yielded greater diagnostic accuracy, specificity and sensitivity and decreased interobserver variability. Data sets were collected for both training and validation. Human machine combined performance was also found to be comparable to standalone performance in comparison with medical performance as well.
The use of AI in the analysis of cytopathological samples in research and clinical settings is increasing, and the involvement of pathologists in AI workflows is becoming increasingly important.
细胞病理学检查是诊断实体瘤和血液系统恶性肿瘤的一种工具。在文献中,广泛讨论了人工智能(AI)辅助方法,以提高细胞病理学临床样本诊断的敏感性、特异性和准确性。其中许多工具也已在临床实践中使用。越来越多的文献描述了 AI 在临床环境中的作用,特别是在提高诊断准确性以及提供预测和预后见解方面。
使用数据库 Google、PUBMED(n=450)和 Google Scholar(n=1067)进行了这项系统评价的全面检索,使用的关键词是“人工智能”和“细胞病理学”以及“细针穿刺”和“深度学习”和“机器学习”和“血液系统疾病”和“肺癌”和“巴氏涂片”和“宫颈癌筛查”和“甲状腺癌”和“乳腺癌”和“敏感性”和“特异性”。该搜索侧重于 2020 年至 2024 年期间以英文发表的文献综述和系统评价。研究的纳入和排除如图所示,遵循 PRISMA 指南。筛选了 417 项结果,选择了 34 项研究进行综述。
在筛查宫颈癌、骨髓和外周血涂片以及肺部的良性和恶性病变患者时,AI 辅助方法,特别是机器学习和深度学习(机器学习的一个子集)方法,应用于细胞病理学数据。这些方法提高了诊断准确性、特异性和敏感性,并降低了观察者间的变异性。数据集用于训练和验证。与医生表现相比,人机结合性能也被发现与独立性能相当。
在研究和临床环境中,越来越多地使用 AI 分析细胞病理学样本,病理学家在 AI 工作流程中的参与也变得越来越重要。